Discussion on the genetic mechanisms and efficacy of growth hormone therapy in children with idiopathic short stature.
10.7499/j.issn.1008-8830.2408040
- Author:
Mireguli MAMAT
1
Author Information
1. Pediatric Center, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
- Publication Type:English Abstract
- Keywords:
Child;
Genetic variation;
Idiopathic short stature;
Recombinant human growth hormone
- MeSH:
Humans;
Human Growth Hormone/therapeutic use*;
Growth Disorders/genetics*;
Child;
Body Height/genetics*
- From:
Chinese Journal of Contemporary Pediatrics
2024;26(12):1255-1260
- CountryChina
- Language:Chinese
-
Abstract:
Idiopathic short stature (ISS) is a term that encompasses a group of short stature disorders with unknown etiology. The genetic factors associated with ISS are complex, and the known genetic mechanisms include alterations in hormones, hormone receptors, or related pathways, defects in fundamental cellular processes (such as intracellular signaling pathways and transcriptional regulation), issues with extracellular matrix or paracrine signaling, as well as genetic variations in the genes encoding these proteins. Recombinant human growth hormone (rhGH) therapy is currently an effective clinical method for improving height in children with ISS. However, the efficacy of rhGH treatment on ISS varies among children with different genetic mechanisms. This paper analyzes and elucidates the genetic mechanisms of ISS and the effects of rhGH on ISS based on existing clinical research, aiming to enhance the understanding of ISS and provide references for improving the height of these children.
